A complementary approach to treating antibody-mediated transplant rejection.
Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.
Heeger
Peter S
PS
Renal Division, Mount Sinai School of Medicine, New York, New York 10029, USA. peter.heeger@mssm.edu
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use*; D051056:Complement Inactivating Agents / Q000627:therapeutic use*; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000906:Antibodies; D050718:Complement C1 Inhibitor Protein; D051056:Complement Inactivating Agents; D011994:Recombinant Proteins